{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:53:55Z","timestamp":1794020035820,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Gene Therapies, Inc., sponsored this study.","id":[{"id":"https:\/\/ror.org\/02gd4zp35","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Most children with biallelic\n                    <jats:italic>SMN1<\/jats:italic>\n                    deletions and three\n                    <jats:italic>SMN2<\/jats:italic>\n                    copies develop spinal muscular atrophy (SMA) type 2. SPR1NT (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03505099\">NCT03505099<\/jats:ext-link>\n                    ), a Phase III, multicenter, single-arm trial, investigated the efficacy and safety of onasemnogene abeparvovec for presymptomatic children with biallelic\n                    <jats:italic>SMN1<\/jats:italic>\n                    mutations treated within six postnatal weeks. Of 15 children with three\n                    <jats:italic>SMN2<\/jats:italic>\n                    copies treated before symptom onset, all stood independently before 24\u2009months (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0001; 14 within normal developmental window), and 14 walked independently (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0001; 11 within normal developmental window). All survived without permanent ventilation at 14\u2009months; ten (67%) maintained body weight (\u22653rd WHO percentile) without feeding support through 24\u2009months; and none required nutritional or respiratory support. No serious adverse events were considered treatment-related by the investigator. Onasemnogene abeparvovec was effective and well-tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention.\n                  <\/jats:p>","DOI":"10.1038\/s41591-022-01867-3","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T11:03:47Z","timestamp":1655463827000},"page":"1390-1397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":287,"title":["Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6429-8657","authenticated-orcid":false,"given":"Kevin A.","family":"Strauss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4472-0902","authenticated-orcid":false,"given":"Michelle A.","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2632-0873","authenticated-orcid":false,"given":"Kayoko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Mendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-4061","authenticated-orcid":false,"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-2018","authenticated-orcid":false,"given":"Hugh J.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-7054","authenticated-orcid":false,"given":"Richard S.","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4593-6342","authenticated-orcid":false,"given":"Kathryn J.","family":"Swoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"Zaidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia A.","family":"Chiriboga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-3516","authenticated-orcid":false,"given":"Susan T.","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jena M.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry B.","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Wigderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitra","family":"Tauscher-Wisniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3552-7369","authenticated-orcid":false,"given":"Bryan E.","family":"McGill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-1818","authenticated-orcid":false,"given":"Thomas A.","family":"Macek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"1867_CR1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","volume":"6","author":"DD Coovert","year":"1997","unstructured":"Coovert, D. D. et al. The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet. 6, 1205\u20131214 (1997).","journal-title":"Hum. Mol. Genet."},{"key":"1867_CR2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","volume":"4","author":"MD Mailman","year":"2002","unstructured":"Mailman, M. D. et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet. Med. 4, 20\u201326 (2002).","journal-title":"Genet. Med."},{"key":"1867_CR3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho, M. et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul. Disord. 28, 208\u2013215 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"1867_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/mus.27425","volume":"65","author":"VJ Carson","year":"2022","unstructured":"Carson, V. J. et al. Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy. Muscle Nerve 65, 51\u201359 (2022).","journal-title":"Muscle Nerve"},{"key":"1867_CR5","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.nmd.2020.10.008","volume":"30","author":"F Muntoni","year":"2020","unstructured":"Muntoni, F. et al. Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial. Neuromuscul. Disord. 30, 959\u2013969 (2020).","journal-title":"Neuromuscul. Disord."},{"key":"1867_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico, A., Mercuri, E., Tiziano, F. D. & Bertini, E. Spinal muscular atrophy. Orphanet J. Rare Dis. 6, 71 (2011).","journal-title":"Orphanet J. Rare Dis."},{"key":"1867_CR7","doi-asserted-by":"publisher","first-page":"e0201004","DOI":"10.1371\/journal.pone.0201004","volume":"13","author":"A Chabanon","year":"2018","unstructured":"Chabanon, A. et al. Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study. PLoS ONE 13, e0201004 (2018).","journal-title":"PLoS ONE"},{"key":"1867_CR8","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","volume":"79","author":"P Kaufmann","year":"2012","unstructured":"Kaufmann, P. et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology 79, 1889\u20131897 (2012).","journal-title":"Neurology"},{"key":"1867_CR9","doi-asserted-by":"publisher","first-page":"e587","DOI":"10.1212\/WNL.0000000000011051","volume":"96","author":"F Trucco","year":"2021","unstructured":"Trucco, F. et al. Respiratory trajectories in type 2 and 3 spinal muscular atrophy in the iSMAC cohort study. Neurology 96, e587\u2013e599 (2021).","journal-title":"Neurology"},{"key":"1867_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02065-z","volume":"16","author":"G Coratti","year":"2021","unstructured":"Coratti, G. et al. Motor function in type 2 and 3 SMA patients treated with nusinersen: a critical review and meta-analysis. Orphanet J. Rare Dis. 16, 430 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"1867_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","volume":"26","author":"E Mercuri","year":"2016","unstructured":"Mercuri, E. et al. Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials. Neuromuscul. Disord. 26, 126\u2013131 (2016).","journal-title":"Neuromuscul. Disord."},{"key":"1867_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/acn3.51281","volume":"8","author":"M Annoussamy","year":"2021","unstructured":"Annoussamy, M. et al. Natural history of type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann. Clin. Transl. Neurol. 8, 359\u2013373 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1867_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jpeds.2012.05.067","volume":"162","author":"MA Farrar","year":"2013","unstructured":"Farrar, M. A. et al. Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J. Pediatr. 162, 155\u2013159 (2013).","journal-title":"J. Pediatr."},{"key":"1867_CR14","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel, R. S. et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 83, 810\u2013817 (2014).","journal-title":"Neurology"},{"key":"1867_CR15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","volume":"57","author":"KJ Swoboda","year":"2005","unstructured":"Swoboda, K. J. et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann. Neurol. 57, 704\u2013712 (2005).","journal-title":"Ann. Neurol."},{"key":"1867_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","volume":"21","author":"S Ramdas","year":"2020","unstructured":"Ramdas, S. & Servais, L. New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin. Pharmacother. 21, 307\u2013315 (2020).","journal-title":"Expert Opin. Pharmacother."},{"key":"1867_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1867_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/ijns7030033","volume":"7","author":"K Hale","year":"2021","unstructured":"Hale, K. et al. Landscape of spinal muscular atrophy newborn screening in the United States: 2018\u20132021. Int. J. Neonatal Screen. 7, 33 (2021).","journal-title":"Int. J. Neonatal Screen."},{"key":"1867_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41436-019-0673-0","volume":"22","author":"DST Kariyawasam","year":"2020","unstructured":"Kariyawasam, D. S. T. et al. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet. Med. 22, 557\u2013565 (2020).","journal-title":"Genet. Med."},{"key":"1867_CR20","first-page":"39","volume":"10","author":"M Jedrzejowska","year":"2020","unstructured":"Jedrzejowska, M. Advances in newborn screening and presymptomatic diagnosis of spinal muscular atrophy. Degener. Neurol. Neuromuscul. Dis. 10, 39\u201347 (2020).","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"1867_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3233\/JND-200593","volume":"8","author":"J Friese","year":"2021","unstructured":"Friese, J. et al. Safety monitoring of gene therapy for spinal muscular atrophy with onasemnogene abeparvovec\u2014a single centre experience. J. Neuromuscul. Dis. 8, 209\u2013216 (2021).","journal-title":"J. Neuromuscul. Dis."},{"key":"1867_CR22","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41434-021-00273-7","volume":"28","author":"H Gaber Ali","year":"2021","unstructured":"Gaber Ali, H. et al. Gene therapy for spinal muscular atrophy: the Qatari experience. Gene Ther. 28, 676\u2013680 (2021).","journal-title":"Gene Ther."},{"key":"1867_CR23","doi-asserted-by":"publisher","first-page":"e2022729","DOI":"10.1542\/peds.2020-0729","volume":"146","author":"MA Waldrop","year":"2020","unstructured":"Waldrop, M. A. et al. Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics 146, e2022729 (2020).","journal-title":"Pediatrics"},{"key":"1867_CR24","doi-asserted-by":"publisher","first-page":"P17","DOI":"10.1016\/S2352-4642(21)00287-X","volume":"6","author":"C Wei\u03b2","year":"2022","unstructured":"Wei\u03b2, C. et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc. Health 6, P17\u2013P27 (2022).","journal-title":"Lancet Child Adolesc. Health"},{"key":"1867_CR25","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","volume":"44","author":"JW Day","year":"2021","unstructured":"Day, J. W. et al. Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy. Drug Saf. 44, 1109\u20131119 (2021).","journal-title":"Drug Saf."},{"key":"1867_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/acn3.51519","volume":"9","author":"AM D\u2019Silva","year":"2022","unstructured":"D\u2019Silva, A. M. et al. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. Ann. Clin. Transl. Neurol. 9, 339\u2013350 (2022).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1867_CR27","unstructured":"Servais, L. et al. Real-world treatment patterns and outcomes in patients with spinal muscular atrophy: updated findings from the RESTORE registry. Presented at: World Muscle Society 2021 Congress, 20\u201324 September 2021; Virtual."},{"key":"1867_CR28","unstructured":"Servais, L. et al. The RESTORE Registry: real-world assessments of interventions and long-term outcomes in patients with spinal muscular atrophy. Presented at: British Paediatric Neurology Association 2022 Annual Conference, 19\u201321 January 2022; Virtual."},{"key":"1867_CR29","unstructured":"Servais, L. et al. Effectiveness and safety of onasemnogene abeparvovec in older patients with spinal muscular atrophy (SMA): real-world outcomes from the RESTORE Registry. Presented at: British Paediatric Neurology Association 2022 Annual Conference, 19\u201321 January 2022; Virtual."},{"key":"1867_CR30","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo, D. C. et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul. Disord. 29, 842\u2013856 (2019).","journal-title":"Neuromuscul. Disord."},{"key":"1867_CR31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02379.x","volume":"450","author":"WHO Multicentre Growth Reference Study Group.","year":"2006","unstructured":"WHO Multicentre Growth Reference Study Group. WHO Motor Development Study: windows of achievement for six gross motor development milestones. Acta Paediatr. Suppl. 450, 86\u201395 (2006).","journal-title":"Acta Paediatr. Suppl."},{"key":"1867_CR32","doi-asserted-by":"publisher","unstructured":"Strauss, K. A. et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy: The Phase III SPR1NT trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-022-01866-4 (2022).","DOI":"10.1038\/s41591-022-01866-4"},{"key":"1867_CR33","doi-asserted-by":"crossref","unstructured":"Bayley, N. Bayley Scales of Infant and Toddler Development: Administration Manual 3rd edn (Pearson PsychCorp, 2006).","DOI":"10.1037\/t14978-000"},{"key":"1867_CR34","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell, J. R. et al. Current clinical applications of in vivo gene therapy with AAVs. Mol. Ther. 29, 464\u2013488 (2021).","journal-title":"Mol. Ther."},{"key":"1867_CR35","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell, J. R. et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 78, 834\u2013841 (2021).","journal-title":"JAMA Neurol."},{"key":"1867_CR36","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day, J. W. et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 20, 284\u2013293 (2021).","journal-title":"Lancet Neurol."},{"key":"1867_CR37","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri, E. et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 20, 832\u2013841 (2021).","journal-title":"Lancet Neurol."},{"key":"1867_CR38","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1212\/WNL.96.15_supplement.4281","volume":"96","author":"RS Finkel","year":"2021","unstructured":"Finkel, R. S. et al. RAINBOWFISH: a study of risdiplam in newborns with presymptomatic spinal muscular atrophy (SMA). Neurology 96, 4281 (2021).","journal-title":"Neurology"},{"key":"1867_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","volume":"231","author":"D Chand","year":"2021","unstructured":"Chand, D. et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J. Pediatr. 231, 265\u2013268 (2021).","journal-title":"J. Pediatr."},{"key":"1867_CR40","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/35057062","volume":"409","author":"International Human Genome Sequencing Consortium.","year":"2001","unstructured":"International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409, 860\u2013921 (2001).","journal-title":"Nature"},{"key":"1867_CR41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ajmg.10008","volume":"106","author":"AE Guttmacher","year":"2001","unstructured":"Guttmacher, A. E., Jenkins, J. & Uhlmann, W. R. Genomic medicine: who will practice it? A call to open arms. Am. J. Med. Genet. 106, 216\u2013222 (2001).","journal-title":"Am. J. Med. Genet."},{"key":"1867_CR42","doi-asserted-by":"publisher","first-page":"e1000347","DOI":"10.1371\/journal.pmed.1000347","volume":"7","author":"WD Hall","year":"2010","unstructured":"Hall, W. D., Mathews, R. & Morley, K. I. Being more realistic about the public health impact of genomic medicine. PLoS Med. 7, e1000347 (2010).","journal-title":"PLoS Med."},{"key":"1867_CR43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nature09792","volume":"470","author":"ES Lander","year":"2011","unstructured":"Lander, E. S. Initial impact of the sequencing of the human genome. Nature 470, 187\u2013197 (2011).","journal-title":"Nature"},{"key":"1867_CR44","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nature09764","volume":"470","author":"ED Green","year":"2011","unstructured":"Green, E. D. & Guyer, M. S. National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature 470, 204\u2013213 (2011).","journal-title":"Nature"},{"key":"1867_CR45","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","volume":"85","author":"TW Prior","year":"2009","unstructured":"Prior, T. W. et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am. J. Hum. Genet. 85, 408\u2013413 (2009).","journal-title":"Am. J. Hum. Genet."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01867-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01867-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01867-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:02:00Z","timestamp":1727395320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01867-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1867"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-01867-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"18 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Novartis Gene Therapies, Inc. sponsored this clinical trial. The authors declare the following competing interests. K.A.S. has received personal compensation from Novartis Gene Therapies, Inc. (formerly AveXis, Inc.) for serving as an advisory board member and from Biogen for serving as a visiting professor, and has received research support from clinical trials sponsored by Novartis Gene Therapies, Inc., and Biogen. M.A.F. has received honoraria for scientific advisory boards from Novartis Gene Therapies, Inc., Biogen, and Roche and research grants from Biogen. F.M. reports grants and personal fees from Novartis Gene Therapies, Inc., including participation in the STR1VE-EU grant and the SPR1NT study; grants, personal fees, and other (participation in the SHINE clinical trial and principal investigator of the investigator-initiated UK SMA REACH UK registry) from Biogen; and grants and personal fees from Roche, including participation in the JEWELFISH clinical trial of risdiplam and participation in the olesoxime clinical trial, during the conduct of the study. F.M. has also received honoraria for scientific advisory boards from Biogen, Novartis, Novartis Gene Therapies, Inc., PTC, Roche, and Sarepta Therapeutics. K.S. has served on advisory boards for Biogen, Novartis Gene Therapies, Inc.\/Novartis, and Chugai (Roche) and has received search funding from Biogen. J.R.M. has received personal compensation for clinical trial consulting and for serving on scientific advisory boards, as well as research support, from Novartis Gene Therapies, Inc. L.S. has received personal compensation as an advisory committee board member\/consultant from Novartis Gene Therapies, Inc., Biogen, Biophytis, Cytokinetics, Dynacure, Roche, Santhera, and Sarepta Therapeutics, and has received research support from Novartis Gene Therapies, Inc., Biogen, Dynacure, and Roche. H.J.M. has received honoraria for scientific advisory boards from Novartis Gene Therapies, Inc., and has received research funding from Roche. R.S.F. has received personal compensation for advisory board participation from Novartis Gene Therapies, Inc., Biogen, Roche, and Scholar Rock, and for consulting from Novartis; editorial fees from Elsevier for co-editing a neurology textbook; license fees from the Children\u2019s Hospital of Philadelphia; and research funding from Novartis Gene Therapies, Inc., Biogen, Roche\/Genentech, and Scholar Rock. K.J.S. has received personal compensation for a speaking engagement from Biogen, and research funding as a principal investigator for clinical trials sponsored by Novartis Gene Therapies, Inc. and Biogen. J.M.K. was site principal investigator for clinical trials sponsored by Novartis Gene Therapies, Inc., Biogen, and Scholar Rock. C.M.Z. has received research support from Biogen. C.A.C. has served on advisory boards for Novartis Gene Therapies, Inc., and Roche\/Genentech; has served as an educational speaker for Biogen; and has received research funding from Novartis Gene Therapies, Inc., Biogen, and Roche. S.T.I. has received personal compensation for service on advisory boards or consulting from Novartis Gene Therapies, Inc., Biogen, Roche\/Genentech, and Sarepta Therapeutics; and research support from Novartis Gene Therapies, Inc., Biogen, Capricor, PTC, Scholar Rock, and Sarepta Therapeutics. J.M.K. is a principal investigator for clinical trials sponsored by Novartis Gene Therapies, Inc., Scholar Rock, and Roche\/Genentech. J.A.P. has served as an investigator on clinical trials for Biogen, Novartis, PTC Therapeutics, and Scholar Rock, and has served in an advisory capacity for Biogen, Scholar Rock, Roche\/Genentech, and Novartis. P.B.S. has served as a consultant for Alexion, Biogen, Genentech, Novartis Gene Therapies, Inc., and Sarepta and has served as a speaker for Alexion, Biogen, Genentech, Grifols, Novartis Gene Therapies, Inc., and PTC Therapeutics. S.K. is an employee of Novartis Gene Therapies, Inc., and receives consulting fees from UCB Pharma, Karuna Therapeutics, Worldwide Clinical Trials, CPC Clinical Research, Zosano Pharmaceuticals, PharPoint Research, and Nesos, Inc. M.W. is an employee of Novartis Gene Therapies, Inc., and owns Novartis stock or other equities. S.T.-W. is an employee of Novartis Gene Therapies, Inc., and owns Novartis stock or other equities. B.E.M. is an employee of Translational Medicine, Novartis Institutes for BioMedical Research (Cambridge), and owns Novartis stock or other equities. T.A.M. is an employee of Novartis Gene Therapies, Inc., and owns Novartis stock or other equities.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}